

# Filgotinib

Catalog No: tcsc2284



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1206161-97-8

**Formula:**

$C_{21}H_{23}N_5O_3S$

**Pathway:**

Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling

**Target:**

JAK;JAK;JAK

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 6.8 mg/mL (15.98 mM; Need ultrasonic and warming); H2O :

**Alternative Names:**

GLPG0634

### Observed Molecular Weight:

425.5


## Product Description

Filgotinib (GLPG0634) is a selective **JAK1** inhibitor with **IC<sub>50</sub>** of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

IC50 & Target: IC50: 10 nM (JAK1), 28 nM (JAK2), 810 nM (JAK3), 116 nM (Tyk2)

**In Vitro:** Filgotinib (GLPG0634) dose-dependently inhibits the differentiation of Th2 cells mediated by IL-4, a cytokine that signals through JAK1 and JAK3. Filgotinib also inhibits Th1 differentiation with similar potencies of 1  $\mu$ M or lower<sup>[1]</sup>. Filgotinib (GLPG0634) does not inhibit JAK2 homodimer-mediated signaling induced by EPO or PRL ( $IC_{50} > 10 \mu$ M)<sup>[2]</sup>.

**In Vivo:** Filgotinib (GLPG0634; 3, 10, 30 mg/kg, p.o.) dose-dependently prevents disease progression in the therapeutic rat CIA model. Filgotinib (50 mg/kg, o.p.) protects bone and cartilage from degradation, effectively reduces infiltration of T cells (CD3<sup>+</sup> cells) and macrophages (F4/80<sup>+</sup> cells) in the paw, and decreases the serum levels of all cytokines and chemokines measured, including IL-6, IP-10, XCL1, and MCP-1<sup>[1]</sup>. Filgotinib (GLPG0634; 0.1 and 0.3 mg/kg) shows efficacy in the rat CIA model<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!